Linezolid clearance during continuous venovenous hemodiafiltration: A case report

被引:22
作者
Kraft, MD
Pasko, DA
DePestel, DD
Ellis, JJ
Peloquin, CA
Mueller, BA
机构
[1] Univ Michigan, Hlth Syst, Dept Pharm Serv, UH B2D301, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Clin Sci, Coll Pharm, Ann Arbor, MI 48109 USA
[3] Natl Jewish Med & Res Ctr, Infect Dis Pharmacokinet Lab, Denver, CO USA
来源
PHARMACOTHERAPY | 2003年 / 23卷 / 08期
关键词
D O I
10.1592/phco.23.8.1071.32874
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective. To determine the linezolid clearance and serum concentrations in a critically ill man receiving continuous venovenous hemodiafiltration (CVVHDF). Methods. Intravenous linezolid 600 mg every 12 hours was administered to a critically ill, 85-year-old man with anuria who was receiving CVVHDF at a dialysate flow rate of 2000 ml/hour and a mean ultrafiltrate production rate of 775 ml/hour. Samples of blood and spent dialysate and ultrafiltrate were obtained at the time of linezolid peaks and troughs, and linezolid concentrations were determined. Results. The CVVHDF yielded a mean linezolid clearance of 36.5 ml/minute and an elimination half-life of 7.5 hours. The linezolid saturation coefficient ranged from 0.77-0.81. Administration of intravenous linezolid 600 mg every 12 hours yielded suitable serum trough concentrations. Conclusion. Administration of intravenous linezolid 600 mg every 12 hours maintained therapeutic serum trough concentrations in this critically ill patient receiving CVVHDE.
引用
收藏
页码:1071 / 1075
页数:5
相关论文
共 21 条
[1]  
[Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P902
[2]  
[Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P565
[3]   Methicillin-resistant Staphylococcus aureus infection in a renal allograft recipient treated successfully with a novel new antimicrobial agent (Linezolid):: New treatment options for infections due to resistant organisms [J].
Antony, SJ ;
Bitter, KM ;
Moreland, T ;
Raudales, F ;
Diaz-Luna, H .
CLINICAL INFECTIOUS DISEASES, 1999, 29 (05) :1341-1342
[4]   Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus (MRSA) [J].
Bassetti, M ;
Di Biagio, A ;
Cenderello, G ;
Del Bono, V ;
Palermo, A ;
Cruciani, M ;
Bassetti, D .
JOURNAL OF INFECTION, 2001, 43 (02) :148-149
[5]  
Brier ME, 1998, J INVEST MED, V46, p276A
[6]   Linezolid [J].
Clemett, D ;
Markham, A .
DRUGS, 2000, 59 (04) :815-827
[7]   Antimicrobial resistance in intensive care units [J].
Fridkin, SK ;
Gaynes, RP .
CLINICS IN CHEST MEDICINE, 1999, 20 (02) :303-+
[8]  
GOLPER TA, 1991, CONTRIB NEPHROL, V93, P110
[9]  
Hussain Z, 2001, SCAND J INFECT DIS, V33, P375, DOI 10.1080/003655401750174048
[10]   A primer on continuous renal replacement therapy for critically ill patients [J].
Joy, MS ;
Matzke, GR ;
Armstrong, DK ;
Marx, MA ;
Zarowitz, BJ .
ANNALS OF PHARMACOTHERAPY, 1998, 32 (03) :362-375